Calidi Biotherapeutics, Inc. (CLDWW) — SEC Filings
Calidi Biotherapeutics, Inc. (CLDWW) — 50 SEC filings. Latest: 10-Q (Nov 13, 2025). Includes 39 8-K, 4 10-Q, 3 S-1.
View Calidi Biotherapeutics, Inc. on SEC EDGAR
Overview
Calidi Biotherapeutics, Inc. (CLDWW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: Calidi Biotherapeutics, Inc. reported a net loss of $5.181 million for the three months ended September 30, 2025, compared to a net loss of $5.069 million for the same period in 2024, representing a 2.2% increase in loss. For the nine months ended September 30, 2025, the net loss was $16.004 million
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bearish, 46 neutral, 2 mixed. The dominant filing sentiment for Calidi Biotherapeutics, Inc. is neutral.
Filing Type Overview
Calidi Biotherapeutics, Inc. (CLDWW) has filed 4 10-Q, 39 8-K, 3 S-1, 1 DEF 14A, 1 8-K/A, 1 SC 13G/A, 1 SC 13G with the SEC between Jun 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of CLDWW's 45 recent filings, 3 were flagged as high-risk, 26 as medium-risk, and 16 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$16.004M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $10.375M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | $6.831M |
Key Executives
- Dr. Jonathan R. Roth
- Dr. Michael J. Ybarra
- Dr. Sarah E. Michaels
- Mr. David M. R. Smith
- Board of Directors
- Mr. David M. E. Smith
- Dr. Xiaolin Liu
- Dr. Lawrence Stern
- Dr. Lawrence E. Stern
Industry Context
Calidi Biotherapeutics operates in the highly competitive and rapidly evolving biotechnology sector, specifically focusing on gene therapies and oncolytic viruses. This industry is characterized by significant R&D investment, long development cycles, and stringent regulatory hurdles. Key trends include advancements in personalized medicine, gene editing technologies, and the increasing focus on immunotherapies for cancer treatment.
Top Tags
financials (7) · material-agreement (7) · corporate-governance (6) · disclosure (5) · management-change (5) · financial-reporting (5) · equity-sale (5) · filing (5) · regulatory (5) · 8-K (4)
Executive Compensation
From the most recent DEF 14A filing (May 23, 2025):
- N/A — N/A: N/A
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (9 months) | $16.004M | Decreased from $18.061M in prior year, an 11.4% reduction. |
| Net Loss (Q3) | $5.181M | Increased from $5.069M in Q3 2024, a 2.2% increase. |
| Cash | $10.375M | Increased from $9.591M at December 31, 2024. |
| Total Liabilities | $6.831M | Decreased significantly from $12.214M at December 31, 2024. |
| Reverse Stock Split | 1-for-12 | Effected on August 4, 2025, reducing outstanding shares. |
| Common Shares Outstanding | 6,906,312 | As of September 30, 2025, post-reverse split. |
| Stock-based compensation (9 months) | $1,658 | A non-cash expense impacting net loss. |
| Net cash provided by financing activities (9 months) | $17,119 | Primary source of cash, including public offerings and warrant exercises. |
| Capital Raise | $10.0M | Amount to be raised in a registered direct offering of common stock and warrants. |
| Filing Date | 2025-07-03 | Date the S-1 was filed with the SEC |
| Central Index Key (CIK) | 0001855485 | Unique identifier for Calidi Biotherapeutics, Inc. |
| SIC Code | 2836 | Standard Industrial Classification for Biological Products (No Diagnostic Substances) |
| Latest Quarter End | 2025-03-31 | End date for the most recent financial period reported in the S-1 |
| Latest Fiscal Year End | 2024-12-31 | End date for the most recent fiscal year reported in the S-1 |
| Annual Meeting Date | July 9, 2025 | Date stockholders will vote on key proposals |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Calidi Biotherapeutics, Inc. (CLDWW)?
Calidi Biotherapeutics, Inc. has 50 recent SEC filings from Jun 2024 to Nov 2025, including 39 8-K, 4 10-Q, 3 S-1. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CLDWW filings?
Across 50 filings, the sentiment breakdown is: 2 bearish, 46 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Calidi Biotherapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Calidi Biotherapeutics, Inc. (CLDWW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Calidi Biotherapeutics, Inc.?
Key financial highlights from Calidi Biotherapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CLDWW?
The investment thesis for CLDWW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Calidi Biotherapeutics, Inc.?
Key executives identified across Calidi Biotherapeutics, Inc.'s filings include Dr. Jonathan R. Roth, Dr. Michael J. Ybarra, Dr. Sarah E. Michaels, Mr. David M. R. Smith, Board of Directors and 4 others.
What are the main risk factors for Calidi Biotherapeutics, Inc. stock?
Of CLDWW's 45 assessed filings, 3 were flagged high-risk, 26 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Calidi Biotherapeutics, Inc.?
Forward guidance and predictions for Calidi Biotherapeutics, Inc. are extracted from SEC filings as they are enriched.